TrialCancer immunology, immunotherapy : CII2020

A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.

Yanina Jansen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.